Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesDocetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy
The Prostate, 07/06/09
Kuroda K et al. - While DOC did not affect PSMA expression, it was unexpectedly found to down-regulate AR and PSA. DOC-induced down-regulation of AR might be one of the anti-tumor mechanisms active in PC. Down-regulation of PSA may account for the significantly higher PSA response rates (45-50%) relative to measurable response rates (8-17%) reported in DOC PC trials and have implications for PSA surrogacy observations derived from DOC trials.
Related Articles
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Relevance Score: 93%
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 91%
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Relevance Score: 89%
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/09
Relevance Score: 88%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Mutation analysis of the MSMB gene in familial prostate cancer
British Journal of Cancer, 12/11/09
Small Variations in Crucial Steps of Tunel Assay Coupled to Flow Cytometry Greatly Affect Measures of Sperm DNA Fragmentation
Journal of Andrology, 12/09/09
Estrogen Receptor alpha and beta Polymorphisms Are Associated with Semen Quality
Journal of Andrology, 12/08/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence
Cancer, 12/11/09
[F18]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study
European Journal of Cancer, 12/11/09
HNF1B and JAZF1 genes, diabetes, and prostate cancer risk
The Prostate, 12/11/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence
Cancer, 12/11/09
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia
Current Opinion in Urology, 12/11/09
Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia
Current Opinion in Urology, 12/11/09
Article Search
Sponsor